feed,title,long_url,short_url
Benzinga,"In Eli Lilly's Lebrikizumab Atopic Dermatitis Study, Majority Of Patients Maintained Skin Clearance At One Year",https://benzinga.com/general/biotech/22/06/27589660/majority-of-patients-maintained-skin-clearance-at-one-year-in-eli-lillys-lebrikizumab-atopic-derm,https://bit.ly/3MpMmBE
Benzinga,Eli Lilly Presents New Analyses On Tirzepatide Injection For Type 2 Diabetes,https://benzinga.com/general/biotech/22/06/27588824/eli-lilly-presents-new-analyses-on-tirzepatide-injection-for-type-2-diabetes,https://bit.ly/39hxF5Q
Benzinga,"Merck, Ridgeback Announce New Molnupiravir Data From Late-Stage COVID-19 Study",https://benzinga.com/general/biotech/22/06/27587236/merck-ridgeback-announce-new-molnupiravir-data-from-late-stage-covid-19-study,https://bit.ly/3aBq0jm
